Medipharm Historical Financial Ratios

LABS Stock

CAD 0.10 0.02 16.67%

Medipharm Labs is lately reporting on over 96 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Days Sales Outstanding of 70.75 will help investors to properly organize and evaluate Medipharm Labs Corp financial condition quickly.

Quick Ratio Current Ratio

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Medipharm Labs Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

About Medipharm Financial Ratios Analysis

Medipharm Labs CorpFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Medipharm Labs investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Medipharm financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Medipharm Labs history.

Medipharm Labs Financial Ratios Chart

At this time, Medipharm Labs' Current Ratio is very stable compared to the past year. As of the 28th of March 2025, Tangible Book Value Per Share is likely to grow to 0.24, while Price To Sales Ratio is likely to drop 0.78.

Price To Sales Ratio Ptb Ratio Days Sales Outstanding Pb Ratio

Add Fundamental

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Medipharm Labs Corp stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Medipharm Labs sales, a figure that is much harder to manipulate than other Medipharm Labs Corp multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Ptb Ratio

Price-to-Book ratio, a financial valuation metric used to compare a company's current market price to its book value. It provides insight into the value that market participants place on the company's equity relative to its net asset value.

Most ratios from Medipharm Labs' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Medipharm Labs Corp current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Medipharm Labs Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

	2022	2023	2024	2025 (projected)
Days Sales Outstanding	214.62	64.76	74.47	70.75
PTB Ratio	0.35	0.45	0.51	0.49

Days Sales Outstanding Ptb Ratio

Medipharm Labs fundamentals Correlations

	Price To Sales Ratio	Ptb Ratio	Days Sales Outstanding	Book Value Per Share	Free Cash Flow Yield	Operating Cash Flow Per Share	Capex To Depreciation	Pb Ratio	Ev To Sales	Free Cash Flow Per Share	Roic	Inventory Turnover	Net Income Per Share	Days Of Inventory On Hand	Payables Turnover	Capex To Revenue	Cash Per Share	Pocfratio	Interest Coverage	Capex To Operating Cash Flow	Pfcf Ratio	Days Payables Outstanding	Income Quality	Roe	Ev To Operating Cash Flow	Pe Ratio
Price To Sales Ratio		0.92	0.53	-0.46	0.87	0.39	0.93	0.92	1.0	0.09	-0.25	-0.92	0.19	0.99	-0.9	1.0	0.05	-0.59	0.33	0.86	-0.8	1.0	0.22	-0.37	-0.58	-0.41
Ptb Ratio	0.92		0.47	-0.6	0.81	0.55	0.85	1.0	0.92	0.16	-0.43	-0.85	0.17	0.91	-0.83	0.92	0.01	-0.51	0.29	0.97	-0.8	0.92	0.19	-0.56	-0.5	-0.38
Days Sales Outstanding	0.53	0.47		-0.25	0.4	0.0	0.37	0.47	0.52	0.02	-0.16	-0.19	-0.57	0.41	-0.3	0.53	0.08	-0.29	-0.02	0.46	-0.41	0.51	0.38	-0.47	-0.29	-0.48
Book Value Per Share	-0.46	-0.6	-0.25		-0.15	-0.84	-0.19	-0.6	-0.45	-0.44	0.58	0.37	-0.05	-0.46	0.32	-0.44	0.75	0.02	0.05	-0.61	0.31	-0.48	-0.73	0.65	0.0	0.78
Free Cash Flow Yield	0.87	0.81	0.4	-0.15		0.24	0.93	0.81	0.87	-0.02	-0.12	-0.85	0.27	0.86	-0.79	0.87	0.39	-0.62	0.58	0.75	-0.76	0.86	-0.13	-0.2	-0.61	-0.06
Operating Cash Flow Per Share	0.39	0.55	0.0	-0.84	0.24		0.22	0.55	0.37	0.64	-0.34	-0.43	0.49	0.42	-0.39	0.35	-0.58	-0.2	-0.06	0.6	-0.41	0.41	0.47	-0.34	-0.18	-0.54
Capex To Depreciation	0.93	0.85	0.37	-0.19	0.93	0.22		0.85	0.93	-0.13	-0.21	-0.94	0.31	0.93	-0.93	0.93	0.36	-0.56	0.36	0.77	-0.73	0.93	-0.15	-0.26	-0.55	-0.05
Pb Ratio	0.92	1.0	0.47	-0.6	0.81	0.55	0.85		0.92	0.16	-0.43	-0.85	0.17	0.91	-0.83	0.92	0.01	-0.51	0.29	0.97	-0.8	0.92	0.19	-0.56	-0.5	-0.38
Ev To Sales	1.0	0.92	0.52	-0.45	0.87	0.37	0.93	0.92		0.07	-0.25	-0.93	0.18	0.99	-0.9	1.0	0.05	-0.59	0.34	0.86	-0.8	1.0	0.21	-0.37	-0.58	-0.4
Free Cash Flow Per Share	0.09	0.16	0.02	-0.44	-0.02	0.64	-0.13	0.16	0.07		0.41	-0.05	0.35	0.1	-0.03	0.06	-0.52	-0.57	-0.14	0.36	-0.51	0.1	0.58	0.27	-0.57	-0.62
Roic	-0.25	-0.43	-0.16	0.58	-0.12	-0.34	-0.21	-0.43	-0.25	0.41		0.21	0.24	-0.24	0.21	-0.25	0.2	-0.55	-0.06	-0.29	-0.18	-0.25	-0.07	0.93	-0.57	0.08
Inventory Turnover	-0.92	-0.85	-0.19	0.37	-0.85	-0.43	-0.94	-0.85	-0.93	-0.05	0.21		-0.48	-0.97	0.95	-0.92	-0.1	0.56	-0.36	-0.78	0.74	-0.93	-0.02	0.22	0.55	0.2
Net Income Per Share	0.19	0.17	-0.57	-0.05	0.27	0.49	0.31	0.17	0.18	0.35	0.24	-0.48		0.29	-0.45	0.17	0.01	-0.36	-0.02	0.2	-0.32	0.22	-0.26	0.43	-0.36	0.19
Days Of Inventory On Hand	0.99	0.91	0.41	-0.46	0.86	0.42	0.93	0.91	0.99	0.1	-0.24	-0.97	0.29		-0.93	0.99	0.03	-0.59	0.34	0.85	-0.79	0.99	0.19	-0.33	-0.58	-0.37
Payables Turnover	-0.9	-0.83	-0.3	0.32	-0.79	-0.39	-0.93	-0.83	-0.9	-0.03	0.21	0.95	-0.45	-0.93		-0.89	-0.17	0.54	-0.12	-0.76	0.72	-0.91	0.03	0.24	0.53	0.15
Capex To Revenue	1.0	0.92	0.53	-0.44	0.87	0.35	0.93	0.92	1.0	0.06	-0.25	-0.92	0.17	0.99	-0.89		0.06	-0.59	0.33	0.86	-0.79	1.0	0.21	-0.38	-0.58	-0.4
Cash Per Share	0.05	0.01	0.08	0.75	0.39	-0.58	0.36	0.01	0.05	-0.52	0.2	-0.1	0.01	0.03	-0.17	0.06		-0.2	0.21	-0.03	-0.11	0.03	-0.86	0.22	-0.2	0.78
Pocfratio	-0.59	-0.51	-0.29	0.02	-0.62	-0.2	-0.56	-0.51	-0.59	-0.57	-0.55	0.56	-0.36	-0.59	0.54	-0.59	-0.2		-0.2	-0.64	0.92	-0.59	-0.11	-0.35	1.0	0.28
Interest Coverage	0.33	0.29	-0.02	0.05	0.58	-0.06	0.36	0.29	0.34	-0.14	-0.06	-0.36	-0.02	0.34	-0.12	0.33	0.21	-0.2		0.25	-0.25	0.29	-0.11	-0.05	-0.19	0.04
Capex To Operating Cash Flow	0.86	0.97	0.46	-0.61	0.75	0.6	0.77	0.97	0.86	0.36	-0.29	-0.78	0.2	0.85	-0.76	0.86	-0.03	-0.64	0.25		-0.89	0.86	0.26	-0.46	-0.62	-0.45
Pfcf Ratio	-0.8	-0.8	-0.41	0.31	-0.76	-0.41	-0.73	-0.8	-0.8	-0.51	-0.18	0.74	-0.32	-0.79	0.72	-0.79	-0.11	0.92	-0.25	-0.89		-0.8	-0.19	0.02	0.91	0.39
Days Payables Outstanding	1.0	0.92	0.51	-0.48	0.86	0.41	0.93	0.92	1.0	0.1	-0.25	-0.93	0.22	0.99	-0.91	1.0	0.03	-0.59	0.29	0.86	-0.8		0.22	-0.37	-0.58	-0.41
Income Quality	0.22	0.19	0.38	-0.73	-0.13	0.47	-0.15	0.19	0.21	0.58	-0.07	-0.02	-0.26	0.19	0.03	0.21	-0.86	-0.11	-0.11	0.26	-0.19	0.22		-0.26	-0.11	-0.98
Roe	-0.37	-0.56	-0.47	0.65	-0.2	-0.34	-0.26	-0.56	-0.37	0.27	0.93	0.22	0.43	-0.33	0.24	-0.38	0.22	-0.35	-0.05	-0.46	0.02	-0.37	-0.26		-0.37	0.31
Ev To Operating Cash Flow	-0.58	-0.5	-0.29	0.0	-0.61	-0.18	-0.55	-0.5	-0.58	-0.57	-0.57	0.55	-0.36	-0.58	0.53	-0.58	-0.2	1.0	-0.19	-0.62	0.91	-0.58	-0.11	-0.37		0.27
Pe Ratio	-0.41	-0.38	-0.48	0.78	-0.06	-0.54	-0.05	-0.38	-0.4	-0.62	0.08	0.2	0.19	-0.37	0.15	-0.4	0.78	0.28	0.04	-0.45	0.39	-0.41	-0.98	0.31	0.27

Click cells to compare fundamentals

Medipharm Labs Account Relationship Matchups

Medipharm Labs fundamentals Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Price To Sales Ratio	2.04	2.13	0.88	0.71	0.82	0.78
Ptb Ratio	0.94	0.56	0.35	0.45	0.51	0.49
Days Sales Outstanding	280.99	284.42	214.62	64.76	74.47	70.75
Book Value Per Share	0.57	0.33	0.2	0.15	0.13	0.24
Operating Cash Flow Per Share	(0.27)	(0.0529)	(0.058)	(0.034)	(0.0391)	(0.041)
Stock Based Compensation To Revenue	0.12	0.0744	0.11	0.13	0.0613	0.0705
Capex To Depreciation	0.69	0.14	0.3	0.19	0.22	0.2
Pb Ratio	0.94	0.56	0.35	0.45	0.51	0.49
Ev To Sales	2.0	0.57	(0.19)	0.24	0.28	0.26
Free Cash Flow Per Share	(0.33)	(0.056)	(0.0612)	(0.0353)	(0.0317)	(0.0333)
Roic	(0.66)	(0.59)	(0.52)	(0.32)	(0.29)	(0.31)
Inventory Turnover	3.61	3.37	3.09	2.75	2.47	2.02
Net Income Per Share	(0.48)	(0.22)	(0.11)	(0.036)	(0.0414)	(0.0435)
Days Of Inventory On Hand	101.02	108.4	118.11	132.8	152.72	225.29
Payables Turnover	14.42	12.36	6.79	12.77	11.5	6.89
Sales General And Administrative To Revenue	0.68	0.85	0.83	0.65	0.59	0.5
Research And Ddevelopement To Revenue	0.0618	0.0624	0.0453	0.006321	0.005689	0.005405
Capex To Revenue	0.21	0.0361	0.039	0.0142	0.0164	0.0156
Cash Per Share	0.16	0.14	0.0899	0.0502	0.0578	0.0549
Pocfratio	(1.94)	(3.5)	(1.21)	(1.91)	(1.72)	(1.81)
Interest Coverage	(9.22)	(4.66)	(952.68)	(50.01)	(57.51)	(60.38)
Capex To Operating Cash Flow	(0.2)	(0.0593)	(0.0537)	(0.0382)	(0.0439)	(0.0417)
Pfcf Ratio	(1.62)	(3.3)	(1.14)	(1.84)	(1.66)	(1.74)
Days Payables Outstanding	25.32	29.54	53.75	28.58	32.86	31.22
Income Quality	0.56	0.24	0.54	0.94	0.85	0.89
Roe	(0.86)	(0.66)	(0.54)	(0.25)	(0.22)	(0.23)
Ev To Operating Cash Flow	(1.91)	(0.93)	0.26	(0.64)	(0.58)	(0.61)
Pe Ratio	(1.09)	(0.84)	(0.65)	(1.81)	(1.62)	(1.54)
Return On Tangible Assets	0.006699	(0.57)	(0.59)	(0.46)	(0.21)	(0.19)
Ev To Free Cash Flow	(1.59)	(0.88)	0.24	(0.62)	(0.56)	(0.59)
Earnings Yield	(0.91)	(1.19)	(1.55)	(0.55)	(0.64)	(0.67)
Net Debt To E B I T D A	0.0272	0.88	0.87	1.5	1.35	1.41
Current Ratio	3.36	7.38	5.01	3.37	3.04	3.08
Tangible Book Value Per Share	0.56	0.33	0.2	0.14	0.13	0.24
Receivables Turnover	1.3	1.28	1.7	5.64	5.07	5.33
Shareholders Equity Per Share	0.57	0.33	0.2	0.15	0.13	0.12
Debt To Equity	0.24	0.002598	0.0113	0.0433	0.0498	0.0473
Capex Per Share	0.0542	0.003133	0.003117	0.001296	0.001491	0.001416

Pair Trading with Medipharm Labs

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Medipharm Labs position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Medipharm Labs will appreciate offsetting losses from the drop in the long position's value.

Moving against Medipharm Stock

0.67	RY	Royal Bank	Pair Corr
0.58	BOFA	Bank of America	Pair Corr
0.41	JPM	JPMorgan Chase	Pair Corr
0.4	CITI	CITIGROUP CDR	Pair Corr

The ability to find closely correlated positions to Medipharm Labs could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Medipharm Labs when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Medipharm Labs - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Medipharm Labs Corp to buy it.

The correlation of Medipharm Labs is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Medipharm Labs moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Medipharm Labs Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Medipharm Labs can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Other Information on Investing in Medipharm Stock

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Price To Sales Ratio	Dividend Yield
Ptb Ratio	Days Sales Outstanding
Book Value Per Share	Free Cash Flow Yield
Invested Capital	Operating Cash Flow Per Share
Average Payables	Stock Based Compensation To Revenue
Capex To Depreciation	Pb Ratio
Ev To Sales	Free Cash Flow Per Share
Roic	Inventory Turnover
Net Income Per Share	Days Of Inventory On Hand
Payables Turnover	Sales General And Administrative To Revenue
Average Inventory	Research And Ddevelopement To Revenue
Capex To Revenue	Cash Per Share
Pocfratio	Interest Coverage
Payout Ratio	Capex To Operating Cash Flow
Pfcf Ratio	Days Payables Outstanding
Net Current Asset Value	Income Quality
Roe	Tangible Asset Value
Ev To Operating Cash Flow	Pe Ratio
Return On Tangible Assets	Ev To Free Cash Flow
Earnings Yield	Intangibles To Total Assets
Net Debt To E B I T D A	Current Ratio
Tangible Book Value Per Share	Receivables Turnover
Shareholders Equity Per Share	Debt To Equity
Capex Per Share	Graham Net Net
Average Receivables	Revenue Per Share
Interest Debt Per Share	Debt To Assets
Enterprise Value Over E B I T D A	Graham Number
Short Term Coverage Ratios	Price Earnings Ratio
Operating Cycle	Price Book Value Ratio
Price Earnings To Growth Ratio	Days Of Payables Outstanding
Dividend Payout Ratio	Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio	Pretax Profit Margin
Ebt Per Ebit	Operating Profit Margin
Effective Tax Rate	Company Equity Multiplier
Long Term Debt To Capitalization	Total Debt To Capitalization
Return On Capital Employed	Debt Equity Ratio
Ebit Per Revenue	Quick Ratio
Dividend Paid And Capex Coverage Ratio	Net Income Per E B T
Cash Ratio	Cash Conversion Cycle
Operating Cash Flow Sales Ratio	Days Of Inventory Outstanding
Days Of Sales Outstanding	Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios	Price To Book Ratio
Fixed Asset Turnover	Capital Expenditure Coverage Ratio
Price Cash Flow Ratio	Enterprise Value Multiple
Debt Ratio	Cash Flow To Debt Ratio
Price Sales Ratio	Return On Assets
Asset Turnover	Net Profit Margin
Gross Profit Margin	Price Fair Value
Return On Equity

Medipharm Historical Financial Ratios

About Medipharm Financial Ratios Analysis

Medipharm Labs Financial Ratios Chart

Price To Sales Ratio

Ptb Ratio

Medipharm Labs fundamentals Correlations

Medipharm Labs Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Medipharm Labs fundamentals Accounts

Pair Trading with Medipharm Labs

Moving against Medipharm Stock

Other Information on Investing in Medipharm Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Ev To Sales	+ 1.0	Price To Sales Ratio
Capex To Revenue	+ 1.0	Price To Sales Ratio
Days Payables Outstanding	+ 1.0	Price To Sales Ratio
Pb Ratio	+ 1.0	Ptb Ratio
Capex To Revenue	+ 1.0	Ev To Sales
Days Payables Outstanding	+ 1.0	Ev To Sales

Pe Ratio	- 0.98	Income Quality
Days Of Inventory On Hand	- 0.97	Inventory Turnover
Inventory Turnover	- 0.94	Capex To Depreciation
Payables Turnover	- 0.93	Days Of Inventory On Hand
Days Payables Outstanding	- 0.93	Inventory Turnover
Inventory Turnover	- 0.93	Ev To Sales